In a move set to transform diagnostic capabilities across the United States federal healthcare landscape, MellingMedical has announced a strategic partnership with CellTivity Scientific. This collaboration marks a significant milestone in medical technology distribution, focused on bringing the cutting-edge Van Gogh Microscopy System—an FDA-classified Class I in vitro diagnostic (IVD) device—to the front lines of care for active-duty military personnel, veterans, and their families.
The Core Innovation: Redefining Tissue Analysis
At the heart of this partnership is the Van Gogh Microscopy System, a platform that utilizes proprietary Dynamic Cell Imaging (DCI) technology. Unlike traditional histopathology, which often requires invasive tissue processing—including fixing, cutting, and staining—the Van Gogh system provides a non-destructive alternative.
By leveraging DCI, the system allows clinicians to examine freshly excised biopsy specimens in real-time. It achieves this by digitally recording metabolic and intracellular activity up to 150µm beneath the tissue surface. Because this optical assessment bypasses the need for physical manipulation, 100% of the sample remains entirely intact. This preservation is critical, as it ensures that the specimen remains available for subsequent molecular analysis, such as next-generation sequencing (NGS), and formal gold-standard pathology.
For federal healthcare providers, the implications are profound. By providing an immediate, high-resolution look at metabolic activity at the point of care, the Van Gogh system serves as a powerful tool to guide intraprocedural tissue sampling. This reduces the risk of “non-diagnostic” biopsies, mitigating delays in diagnosis and curbing the diagnostic inaccuracies that can occur when tissue quality is compromised during initial processing.
A Chronology of Integration: Scaling Advanced Diagnostics
The integration of the Van Gogh system into the federal network is the result of a deliberate, multi-layered strategic effort. While the technology has been moving through the regulatory and validation pathways of the FDA, the finalization of this distribution agreement represents the culmination of efforts to bridge the gap between innovation and clinical application.
Phase 1: Regulatory Validation
The journey began with the rigorous assessment of the Van Gogh system under FDA guidelines. Achieving Class I IVD status served as the foundational prerequisite, confirming the safety and reliability of the device for clinical use.
Phase 2: Strategic Network Alignment
CellTivity Scientific sought a partner capable of navigating the complex procurement infrastructure of the US federal government. MellingMedical, a Service-Disabled Veteran-Owned Small Business (SDVOSB), was selected due to its established track record and extensive contracting reach.
Phase 3: Deployment Strategy
With the partnership formalized, the focus has shifted to the deployment of the hardware across the vast network of the Department of Defense (DoD) and the Department of Veterans Affairs (VA). The rollout is designed to prioritize facilities where rapid, high-accuracy diagnostic turnaround is most critical for patient outcomes, particularly in oncology and surgical oncology settings.
Supporting Data: The Power of the MellingMedical Network
The efficiency of this partnership relies on MellingMedical’s unique position within the federal supply chain. As an SBA-verified SDVOSB, the company holds critical vehicles, including the Medical Equipment and Surgical Federal Supply Schedule (Med/Surg), a Pharmaceutical Schedule, and extensive electronic catalogue (ECAT) capabilities.
This infrastructure is not merely administrative; it is a massive logistical engine that reaches:
- Department of Defense: Over 95 military medical facilities.
- Veterans Affairs: 172 VA Medical Centers and more than 1,138 VA Outpatient Clinics.
- Specialized Care: Seven VA Consolidated Mail Outpatient Pharmacies (VA CMOPs).
- Public Health Infrastructure: Coverage extending to the Department of Health and Human Services (HHS), including the Centers for Disease Control and Prevention (CDC) and the Indian Health Service (IHS).
This distribution reach ensures that the Van Gogh Microscopy System will not be limited to high-level research hospitals but will instead be accessible in clinical settings that serve a broad spectrum of the veteran population.

Official Perspectives: Aligning Vision and Execution
The leadership of both organizations has expressed strong confidence in the synergy created by this alliance. For Chris Melling, founder and CEO of MellingMedical, the partnership is a direct fulfillment of his company’s mission to provide “best-in-class” technology to those who have served the nation.
"CellTivity’s track record of engineering high-quality, innovative diagnostic workflow solutions makes them an ideal ally for serving federal healthcare providers," Melling stated during the announcement. "Their specialized focus on cutting-edge technologies like the Van Gogh system will provide federal healthcare clinicians with the tools they need to enhance diagnostic confidence, maximize tissue sufficiency for next-generation sequencing, and deliver timely, optimal patient care."
From the perspective of CellTivity Scientific, the partnership acts as a force multiplier. By leveraging MellingMedical’s existing relationships, CellTivity can bypass the arduous process of establishing individual contracts with hundreds of facilities, allowing them to focus on training, support, and the technical evolution of the Van Gogh platform.
Implications for the Future of Federal Healthcare
The introduction of the Van Gogh system into the VA and DoD networks signals a broader shift toward "precision diagnostics" within the public sector.
1. The End of "Guesswork" in Biopsies
One of the most persistent challenges in oncology is the "non-representative sample." If a biopsy is taken from an area of tissue that is metabolically inactive, the resulting diagnosis may be inaccurate. The Van Gogh system’s ability to map metabolic activity before the specimen is fully removed allows surgeons and oncologists to pinpoint the most active sites of disease, ensuring the sample is biologically meaningful.
2. Streamlining the Diagnostic Workflow
Current pathology workflows are often bottlenecked by the physical processing of tissue. By providing real-time data, the Van Gogh system allows for "intraprocedural" decision-making. If a clinician can confirm the presence of malignant cells while the patient is still on the table, the need for repeat procedures is drastically reduced. This saves time, reduces anesthesia exposure for the patient, and lowers the overall cost per case for the healthcare system.
3. Preserving Tissue for the Genomic Era
As medicine moves toward personalized, molecularly-driven treatments, the need for high-quality tissue is greater than ever. Next-generation sequencing (NGS) requires a specific amount of high-quality, preserved genetic material. Traditional biopsy methods can sometimes damage the DNA or RNA within a sample due to the chemicals used in staining or the heat generated during processing. Because the Van Gogh system is non-destructive, it provides a perfect, pristine sample for the downstream genomic testing that informs modern immunotherapy and targeted cancer treatments.
4. Supporting the Veteran Experience
For veterans and active-duty personnel, who often rely on a centralized system for their comprehensive healthcare, this technology represents a significant upgrade in the quality of care. Faster diagnosis leads to shorter wait times for treatment initiation, which is the most critical variable in cancer prognosis. By placing the Van Gogh system into VA centers across the country, the government is effectively democratizing access to state-of-the-art diagnostic technology.
Conclusion
The partnership between MellingMedical and CellTivity Scientific is more than a commercial agreement; it is an infrastructure investment in the future of federal medicine. By combining the logistical prowess of a veteran-focused distributor with the high-tech precision of Dynamic Cell Imaging, the federal government is positioning its healthcare network to lead in the diagnostic space.
As the Van Gogh Microscopy System is deployed across the DoD and VA, the healthcare community will be watching closely. If the system performs as expected, it could set a new standard for diagnostic workflow in oncology, turning the "wait and see" model into a "see and act" reality. For the millions of Americans who depend on the federal healthcare system, this shift promises not just better diagnostics, but better outcomes, shorter wait times, and a higher standard of care for those who have sacrificed the most.
